References
1. Park BJ. Prospectus of the Korean Society for Pharmacoepidemiology and Risk Management. J Pharmacoepidemiol Risk Manag 2008. 15–7.
2. Korea Food and Drug Administration. Pharmacovigilance Research Network. Standard operation procedures for pharmacovigilance research network regional pharmacovigilance centers 2011. Seoul: Pharmacovigilance Research Network;
3. Choi NK, Park BJ. Adverse drug reaction surveillance system in Korea. J Prev Med Public Health 2007. 40278–284.
4. Jang BW. Pharmaceutical affairs law and administration 2012. Seoul: SinilBooks; 520.
5. Uppsala Monitoring Center. Active ICSRS in the WHO global ICSR database per million inhabitants and year [Internet] 2012. cited 2012 Aug 27. Uppsala: Uppsala Monitoring Center; Available from:
http://who-umc.org/graphics/26930.gif.
7. Evans SJ, Waller PC, Davis S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf 2001. 10483–486.
8. Rothman KJ, Lanes S, Sacks ST. The reporting odds ratio and its advantages over the proportional reporting ratio. Pharmacoepidemiol Drug Saf 2004. 13519–523.
9. Bate A, Lindquist M, Edwards IR, Olsson S, Orre R, Lansner A, De Freitas RM. A Bayesian neural network method for adverse drug reaction signal generation. Eur J Clin Pharmacol 1998. 54315–321.
10. Seong JM, Choi NK, Ahn SH, Park BJ. Development of signal detection program for adverse drug reaction. J Pharmacoepidemiol Risk Manag 2011. 415–21.
11. Council for International Organizations of Medical Sciences Working Group VIII. Practical aspects of signal detection in pharmacovigilance: report of CIOMS Working Group VIII 2010. Geneva: Council for International Organizations of Medical Sciences;
12. Stahl M, Lindquist M, Edwards IR, Brown EG. Introducing triage logic as a new strategy for the detection of signals in the WHO Drug Monitoring Database. Pharmacoepidemiol Drug Saf 2004. 13355–363.
13. Center for Drug Evaluation and Research (US). Center for Biologics Evaluation and Research (US). Guidance for industry: good pharmacovigilance practices and pharmacoepidemiologic assessment 2005. Rockville: US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research;
14. Waller PC, Tilson HH. In : Stephens MD, Talbot JC, Waller P, eds. Managing drug safety issues with marketed products. Stephens' detection of new adverse drug reactions 2004. 5th edth ed. Hoboken: John Wiley & Sons; 345–374.
15. Loke YK, Price D, Herxheimer A. Cochrane Adverse Effects Methods Group. Systematic reviews of adverse effects: framework for a structured approach. BMC Med Res Methodol 2007. 732.
16. Hall GC, Sauer B, Bourke A, Brown JS, Reynolds MW, Casale RL. Guidelines for good database selection and use in pharmacoepidemiology research. Pharmacoepidemiol Drug Saf 2012. 211–10.
17. Choi NK, Hahn S, Park BJ. Increase in mortality rate following coprescription of cisapride and contraindicated drugs. Ann Pharmacother 2007. 41667–673.
18. Park BJ. Drug utilization review. J Pharmacoepidemiol Risk Manag 2008. 113–19.
19. Choi NK, Park BJ. Strategy for establishing an effective Korean drug utilization review system. J Korean Med Assoc 2010. 531130–1138.